Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 19/20 | 0.65 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.65 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2240672 | 1.00 | FFAR1 (0.65) | FFAR1CHRM5SLC6A3PPARGPOLB | |
| SCHEMBL12348769 | 0.97 | FFAR1 (0.64) | FFAR1CHRM5SLC6A3PPARGPOLB | |
| SCHEMBL12348774 | 0.97 | FFAR1 (0.64) | FFAR1CHRM5SLC6A3PPARGPOLB | |
| SCHEMBL2246583 | 0.87 | FFAR1 (0.61) | FFAR1CHRM5SLC6A3PPARG | |
| SCHEMBL2246575 | 0.87 | FFAR1 (0.61) | FFAR1CHRM5SLC6A3PPARG | |
| SCHEMBL2246573 | 0.87 | FFAR1 (0.61) | FFAR1CHRM5SLC6A3PPARG | |
| SCHEMBL2242722 | 0.85 | FFAR1 (0.59) | FFAR1CHRM5SLC6A3PPARG | |
| SCHEMBL2242726 | 0.85 | FFAR1 (0.59) | FFAR1CHRM5SLC6A3PPARG | |
| SCHEMBL2242733 | 0.85 | FFAR1 (0.59) | FFAR1CHRM5SLC6A3PPARG | |
| SCHEMBL2242590 | 0.83 | FFAR1 (0.69) | FFAR1CHRM5SLC6A3PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003648-B2 | Heterocyclic GPR40 modulators | AMGEN INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-7714008-B2 | Heterocyclic GPR40 modulators | AMGEN INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100075974-A1 | HETEROCYCLIC GPR40 MODULATORS | AMGEN INC. (US) | 2010-03-25 | — | — | US | disclosed |
| EP-2064193-A1 | HETEROCYCLIC GPR40 MODULATORS | Amgen, Inc (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20080090840-A1 | Heterocyclic GPR40 Modulators | AMGEN INC. (US) | 2008-04-17 | — | — | US | disclosed |
| WO-2008030520-A1 | HETEROCYCLIC GPR40 MODULATORS | AMGEN INC. (US) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075974-A1 | HETEROCYCLIC GPR40 MODULATORS | GPR119, GPR55, GPR65 | FFAR1 25/4885CHRM5 308/4885SLC6A3 3204/4885 |
| US-20080090840-A1 | Heterocyclic GPR40 Modulators | GPR119, GPR55, GPR65 | FFAR1 25/4885CHRM5 308/4885SLC6A3 3204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.